A rising hematocrit is the most common thing that happens to men on testosterone, and 54% is the number at which guidelines say to stop and investigate. What we see readers get wrong most often is treating that figure as a measured danger line. It is closer to a borrowed convention, and the rise itself is the expected effect of the drug rather than a sign something has gone wrong.
The number also moves for reasons that have nothing to do with the therapy. Sleep apnoea, smoking, altitude, and simple dehydration at the draw all push it up.
The Verdict
What Hematocrit Measures
Hematocrit is the share of your blood volume made up of red cells, written as a percentage. A reading of 48% means red cells occupy 48% of the sample and plasma the remaining 52%. It moves with haemoglobin and red cell count, and a full blood count reports all three together.
Because it is a ratio, plasma volume changes it directly. Lose fluid and the percentage climbs even though the number of red cells has not changed at all. This is the single most common reason a reading crosses a threshold once and then does not repeat. Our page on red blood cell count covers the related markers on the same panel.
Why Testosterone Raises It
Testosterone increases red cell production through two mechanisms working together. The first is iron supply. Testosterone suppresses hepcidin, the liver hormone that restricts how much iron is absorbed from food and released from storage, so more iron reaches the bone marrow.
The second is the signal itself. Testosterone raises erythropoietin, the kidney hormone that tells the marrow to make red cells. It also appears to reset the relationship between erythropoietin and haemoglobin, so the body defends a higher count than it did before treatment. The effect is dose related. It usually appears within the first three to six months, which is why that is when the guideline asks for the second measurement.
Delivery Route Changes the Odds More Than Dose Does
| Route | Reported rate of erythrocytosis | Why |
|---|---|---|
| Short-acting injections (cypionate, enanthate) | Highest reported rates, around 40% in review data | Each injection produces a peak well above the physiological range before falling, and that peak drives red cell production |
| Transdermal gels and creams | Lowest, around 10% to 15% | Daily dosing keeps levels flatter, so there is no supraphysiological spike |
| Implanted pellets | Intermediate to high, reported near 35% | A large depot released over months, with an early phase above target |
| Nasal and oral formulations | Lower, though studied in far fewer men | Short peaks and rapid clearance, with much less published follow-up than injections |
The pattern across those rows is about peaks rather than totals. An intramuscular injection of testosterone cypionate pushes levels well above the physiological range in the days that follow, then lets them fall. That early spike is the stimulus the marrow responds to. A gel applied every day delivers a similar weekly total without ever producing the peak.
This is the practical reason two men on the same weekly milligram total can sit twenty points apart on hematocrit. Our comparison of TRT injections, cream, and pellets covers what else changes with the route.
Where the 54% Threshold Came From
The threshold is a convention rather than a finding. It was inherited from the diagnostic criteria for polycythaemia vera and from older transfusion and aviation medicine. In those settings, a hematocrit above the mid-fifties marked the point at which blood viscosity rises steeply. No trial has randomised men on testosterone by hematocrit and counted clots on either side of that line.
That does not make the number useless. It is a reasonable place to pause, repeat the test, and look for a second cause. It does mean a reading of 53% is not safe and 55% is not dangerous in the way the framing implies. The evidence underneath the threshold is thinner than the confidence with which it gets quoted.
The clot question is separately unresolved. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, followed 5,246 men with hypogonadism and cardiovascular risk and found no excess of major cardiac events on testosterone gel. It did record more pulmonary embolism in the testosterone group, alongside more atrial fibrillation and acute kidney injury. That is a signal worth respecting without treating it as settled, and it came from the flattest delivery route rather than the peaky one.
What Else Pushes It Up
| Cause | Mechanism | What it means for the reading |
|---|---|---|
| Testosterone therapy itself | Suppresses hepcidin and raises erythropoietin, so more iron reaches the marrow and more red cells are made | The expected effect, not a complication in itself |
| Untreated sleep apnoea | Repeated overnight oxygen dips drive erythropoietin up independently of any drug | A rising hematocrit is sometimes the first hard evidence of it |
| Smoking | Carbon monoxide displaces oxygen, and the marrow compensates | Often the largest single contributor when present |
| Dehydration at the draw | Hematocrit is a ratio of cells to plasma. Less plasma raises the number with no change in red cell mass | A morning draw after a sauna or a hard session can read several points high |
| Living at altitude | Lower oxygen pressure raises the set point | Shifts the whole distribution up, so the same number means something different |
| Polycythaemia vera | A bone marrow disorder, usually driven by a JAK2 mutation | A different disease with different risks. Testing separates it from a drug effect |
Sleep apnoea deserves separate attention because the relationship runs both ways. Untreated apnoea raises hematocrit on its own through repeated overnight oxygen dips, and testosterone can worsen apnoea in men who already have it. A hematocrit that climbs faster than the dose explains is one of the more useful reasons to ask about snoring, witnessed pauses, and daytime sleepiness. Our guide to sleep need covers the symptom picture.
Who This Does Not Apply To
A high hematocrit in a man who is not on testosterone is a different investigation entirely, and nothing here should be read across to it. The same is true if the full blood count shows platelets or white cells rising alongside the red cells. That pattern points toward a marrow disorder rather than a drug effect, and it needs proper haematology input.
What would change our reading of the 54% line: a trial that followed men on testosterone therapy across hematocrit bands and counted venous thromboembolism in each. If that showed a real inflection at 54%, the threshold would stop being a convention and start being a measurement. If it showed the curve is flat until much higher, a great deal of dose reduction and blood donation currently happening would turn out to have been unnecessary.
Frequently Asked Questions
What hematocrit is too high on TRT?
54% is the number clinical guidelines act on. The Endocrine Society guideline on testosterone therapy advises measuring hematocrit before starting, again at three to six months, then annually, and stopping therapy to investigate if it passes 54%. Where the number came from is worth knowing. It is a convention carried over from the diagnosis of polycythaemia vera and from older transfusion medicine. No outcome trial in men on testosterone produced it. No trial has established the hematocrit at which a man on TRT starts having more clots than one who is not.
Why does testosterone raise hematocrit at all?
It works on two levers at once. Testosterone suppresses hepcidin, the hormone that limits how much iron gets absorbed and released from stores, so more iron becomes available to the bone marrow. It also raises erythropoietin and appears to reset the relationship between erythropoietin and haemoglobin, so the body defends a higher red cell count than it did before. The effect is dose related and shows up within the first few months for most men.
Do injections cause it more often than gels?
Yes, and by a wide margin. Review data puts erythrocytosis at roughly 40% of men on short-acting injections against roughly 10% to 15% on transdermal gels. The reason is the shape of the curve rather than the total dose. An intramuscular injection produces a peak well above the normal range in the days after it, and that peak stimulates red cell production. A gel applied daily holds a flatter level. Switching route is one of the adjustments a clinician may consider, and it is a conversation to have with the person prescribing.
Does donating blood fix it?
It lowers the number reliably, and whether it lowers risk is unproven. Therapeutic phlebotomy is widely used and no trial has shown it reduces clots in men whose erythrocytosis comes from testosterone. There is a documented cost: repeated phlebotomy depletes iron and can trigger reactive thrombocytosis, a rise in platelets, which is not obviously helpful if the aim is to reduce clotting risk. Some clinicians prefer adjusting the dose or the delivery route first. That decision belongs with the prescriber who can see the full picture.
Is high hematocrit on TRT the same as polycythaemia?
No, and the distinction matters for how seriously to take it. Polycythaemia vera is a bone marrow disorder, usually driven by a JAK2 mutation, in which the marrow produces red cells, and often platelets and white cells, without any signal telling it to. Testosterone-related erythrocytosis is a normal marrow responding correctly to a hormonal signal. The risks are not established to be equivalent, and a JAK2 test plus an erythropoietin level is how the two get separated when the picture is unclear.
Can a high reading be wrong?
Yes, and it happens often enough to be worth checking before anything changes. Hematocrit is the proportion of your blood volume made up of red cells, so anything that reduces plasma volume raises it without a single extra red cell being made. A draw taken dehydrated, after a sauna, after a long training session, or first thing on a hot morning can read several points above a properly hydrated repeat. A single number over a threshold is a reason to repeat the test under normal conditions, not a result to act on immediately.
Related
- TRT side effects and risks — the full profile and what monitoring is meant to catch
- TRT injections vs cream vs pellets — how the delivery route changes everything downstream
- Red blood cell count — the companion marker on the same panel
- Ferritin — how iron stores read after repeated blood donation
- Men's hormone panel — what a proper monitoring panel includes
- Best TRT clinics — how programmes compare on monitoring depth